Literature DB >> 21395539

CYP2A5 induction and hepatocellular stress: an adaptive response to perturbations of heme homeostasis.

Gordon M Kirby1, Kathleen D Nichols, Monica Antenos.   

Abstract

Unlike most cytochrome P450 (CYP) enzymes, murine hepatic CYP2A5 is induced during pathological conditions that result in liver injury including hepatotoxicity mediated by xenobiotics, hepatitis caused by various microbial agents and liver neoplasia. Since CYP2A5 metabolizes various important xenobiotics including nicotine and pro-carcinogens such as nitrosamines and aflatoxin B(1), altered gene expression could affect tobacco addiction, hepatotoxicity and hepatocarcinogenesis. This article synthesizes the current knowledge concerning hepatic expression of Cyp2a5 including the transcriptional and post-transcriptional regulatory mechanisms, pathophysiological conditions associated with enzyme induction such as oxidative and endoplasmic reticulum stress and altered lipid and energy homeostasis as well as the known exogenous and putative endogenous substrates. Knowledge of the stimuli responsible for the unique overexpression of CYP2A5 during liver injury may provide clues to a functional role for this enzyme and the impact of variable CYP2A5 expression on xenobiotic metabolism and toxicity, disease development and the adaptive response to hepatocellular stress.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21395539     DOI: 10.2174/138920011795016845

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  14 in total

Review 1.  Alcoholic Liver Disease: from CYP2E1 to CYP2A5.

Authors:  Tung Ming Leung; Yongke Lu
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

2.  Alcoholic fatty liver is enhanced in CYP2A5 knockout mice: The role of the PPARα-FGF21 axis.

Authors:  Xue Chen; Stephen C Ward; Arthur I Cederbaum; Huabao Xiong; Yongke Lu
Journal:  Toxicology       Date:  2017-01-25       Impact factor: 4.221

3.  CYP2A6 is associated with obesity: studies in human samples and a high fat diet mouse model.

Authors:  Kesheng Wang; Xue Chen; Stephen C Ward; Ying Liu; Youssoufou Ouedraogo; Chun Xu; Arthur I Cederbaum; Yongke Lu
Journal:  Int J Obes (Lond)       Date:  2018-02-20       Impact factor: 5.095

4.  Absence of cytochrome P450 2A5 enhances alcohol-induced liver injury in mice.

Authors:  Feng Hong; Xiyu Liu; Stephen S Ward; Huabao Xiong; Arthur I Cederbaum; Yongke Lu
Journal:  Dig Liver Dis       Date:  2015-03-06       Impact factor: 4.088

5.  Strain-specific altered nicotine metabolism in 3,3'-diindolylmethane (DIM) exposed mice.

Authors:  A Joseph Bloom; Pramod Upadhyaya; Evan D Kharasch
Journal:  Biopharm Drug Dispos       Date:  2019-05-20       Impact factor: 1.627

6.  Alcohol Upregulation of CYP2A5: Role of Reactive Oxygen Species.

Authors:  Yongke Lu; Arthur I Cederbaum
Journal:  React Oxyg Species (Apex)       Date:  2016-03

7.  The role of CYP2A5 in liver injury and fibrosis: chemical-specific difference.

Authors:  Feng Hong; Chuanping Si; Pengfei Gao; Arthur I Cederbaum; Huabao Xiong; Yongke Lu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-09-12       Impact factor: 3.000

8.  Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.

Authors:  Meghan J Chenoweth; Maria Novalen; Larry W Hawk; Robert A Schnoll; Tony P George; Paul M Cinciripini; Caryn Lerman; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-10       Impact factor: 4.254

9.  Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease.

Authors:  Rana V Smalling; Don A Delker; Yuxia Zhang; Natalia Nieto; Michael S McGuiness; Shuanghu Liu; Scott L Friedman; Curt H Hagedorn; Li Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-06-27       Impact factor: 4.052

Review 10.  Cytochrome P450s and Alcoholic Liver Disease.

Authors:  Yongke Lu; Arthur I Cederbaum
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.